Federal Register / Vol. 89, No. 243 / Wednesday, December 18, 2024 / Notices 102953 

and a final determination containing 

such findings, and may result in the 

issuance of an exclusion order or a cease 

and desist order or both directed against 

the respondent. 

By order of the Commission. 

Issued: December 13, 2024. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2024–29977 Filed 12–17–24; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation Nos. 701–TA–750 and 731– 

TA–1728 (Preliminary)] 

Sol Gel Alumina-Based Ceramic 

Abrasive Grains From China; Revised 

Schedule for the Subject 

Investigations 

AGENCY: United States International 

Trade Commission. 

ACTION: Notice. 

DATES: December 13, 2024. 

FOR FURTHER INFORMATION CONTACT: 

Keysha Martinez (202–205–2136), Office 

of Investigations, U.S. International 

Trade Commission, 500 E Street SW, 

Washington, DC 20436. Hearingimpaired persons can obtain 

information on this matter by contacting 

the Commission’s TDD terminal on 202– 

205–1810. Persons with mobility 

impairments who will need special 

assistance in gaining access to the 

Commission should contact the Office 

of the Secretary at 202–205–2000. 

General information concerning the 

Commission may also be obtained by 

accessing its internet server (https://

www.usitc.gov). The public record for 

these investigations may be viewed on 

the Commission’s electronic docket 

(EDIS) at https://edis.usitc.gov. 

SUPPLEMENTARY INFORMATION: On 

November 25, 2024, the Commission 

established a schedule for the conduct 

of the preliminary phase of the subject 

investigations (89 FR 95235, December 

2, 2024). Subsequently, the Department 

of Commerce (‘‘Commerce’’) extended 

the deadline for its initiation 

determination from December 16, 2024 

to January 6, 2025 (89 FR 100465, 

December 12, 2024). The Commission, 

therefore, is revising its schedule to 

conform with Commerce’s new 

schedule. 

The Commission must reach 

preliminary determinations within 25 

days after the date on which the 

Commission receives notice from 

Commerce of initiation of the 

investigations, and the Commission’s 

views must be transmitted to Commerce 

within five business days thereafter. 

For further information concerning 

this proceeding, see the Commission’s 

notice cited above and the 

Commission’s Rules of Practice and 

Procedure, part 201, subparts A and B 

(19 CFR part 201), and part 207, 

subparts A and B (19 CFR part 207). 

Authority: These investigations are 

being conducted under authority of title 

VII of the Tariff Act of 1930; this notice 

is published pursuant to § 207.12 of the 

Commission’s rules. 

By order of the Commission. 

Issued: December 13, 2024. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2024–30024 Filed 12–17–24; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 337–TA–1427] 

Certain Components for Injection 

Molding Machines, and Products 

Containing the Same; Notice of 

Institution of Investigation 

AGENCY: U.S. International Trade 

Commission. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that a 

complaint was filed with the U.S. 

International Trade Commission on 

November 12, 2024, under section 337 

of the Tariff Act of 1930, as amended, 

on behalf of Husky Injection Molding 

Systems LTD. of Canada and Husky 

Injection Molding Systems, Inc. of 

Milton, Vermont. Husky filed a 

supplemental complaint on November 

29, 2024, and subsequently refiled the 

same ‘‘supplemental’’ complaint as an 

amended complaint on December 2, 

2024. The amended complaint, alleges 

violations of section 337 based upon the 

importation into the United States, the 

sale for importation, and the sale within 

the United States after importation of 

certain components for injection 

molding machines, and products 

containing the same by reason of the 

infringement of certain claims of U.S. 

Patent No. 9,713,891 (‘‘the ’891 patent’’); 

U.S. Patent No. 11,794,375 (‘‘the ’375 

patent’’); U.S. Patent No. 10,093,053 

(‘‘the ’053 patent’’); U.S. Patent No. 

8,834,149 (‘‘the ’149 patent’’); and U.S. 

Patent No. 7,645,132 (‘‘the ’132 patent’’). 

The amended complaint further alleges 

that an industry in the United States 

exists as required by the applicable 

Federal Statute. The complainant 

requests that the Commission institute 

an investigation and, after the 

investigation, issue a limited exclusion 

order and cease and desist orders. 

ADDRESSES: The complaint, except for 

any confidential information contained 

therein, may be viewed on the 

Commission’s electronic docket (EDIS) 

at https://edis.usitc.gov. For help 

accessing EDIS, please email 

EDIS3Help@usitc.gov. Hearing impaired 

individuals are advised that information 

on this matter can be obtained by 

contacting the Commission’s TDD 

terminal on (202) 205–1810. Persons 

with mobility impairments who will 

need special assistance in gaining access 

to the Commission should contact the 

Office of the Secretary at (202) 205– 

2000. General information concerning 

the Commission may also be obtained 

by accessing its internet server at 

https://www.usitc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Susan Orndoff, The Office of Docket 

Services, U.S. International Trade 

Commission, telephone (202) 205–1802. 

SUPPLEMENTARY INFORMATION: 

Authority: The authority for 

institution of this investigation is 

contained in section 337 of the Tariff 

Act of 1930, as amended, 19 U.S.C. 

1337, and in section 210.10 of the 

Commission’s Rules of Practice and 

Procedure, 19 CFR 210.10 (2024). 

Scope of Investigation: Having 

considered the complaint, the U.S. 

International Trade Commission, on 

December 12, 2024, ordered that— 

(1) Pursuant to subsection (b) of 

section 337 of the Tariff Act of 1930, as 

amended, an investigation be instituted 

to determine whether there is a 

violation of subsection (a)(1)(B) of 

section 337 in the importation into the 

United States, the sale for importation, 

or the sale within the United States after 

importation of certain products 

identified in paragraph (2) by reason of 

infringement of one or more of claims 

1–2, 4, and 6–8 of the ’891 patent; 1–3, 

5–15, and 17–21 of the ’375 patent; 

claims 1–4, 6, and 8–10 of the ’053 

patent; claims 1–9 and 18 of the ’149 

patent; and claims 1–4, 7, 10–12, 14–19, 

21–24, and 26 of the ’132 patent, and 

whether an industry in the United 

States exists as required by subsection 

(a)(2) of section 337; 

(2) Pursuant to section 210.10(b)(1) of 

the Commission’s Rules of Practice and 

Procedure, 19 CFR 210.10(b)(1), the 

plain language description of the 

accused products or category of accused 

products, which defines the scope of the 

investigation, is ‘‘mold products, cavity 

insert products, and molding apparatus 

products for injection molding 

machines, components for injection 


khammond on DSK9W7S144PROD with NOTICES
102954 Federal Register / Vol. 89, No. 243 / Wednesday, December 18, 2024 / Notices 

molding machines and products 

containing the same’’; 

(3) For the purpose of the 

investigation so instituted, the following 

are hereby named as parties upon which 

this notice of investigation shall be 

served: 

(a) The complainants are: 

Husky Injection Molding Systems LTD., 

500 Queen Street South, Bolton, 

Ontario, Canada L7E 5S5 

Husky Injection Molding Systems, Inc., 

288 North Road, Milton, VT, USA, 

05468 

(b) The respondent is the following 

entity alleged to be in violation of 

section 337, and is the party upon 

which the complaint is to be served: 

NINGBO AO SHENG MOLD CO., LTD., 

d/b/a AOSIMI, No. 8 Xingde Rd. 

Ditang Ave. YuYao, Zhejiang 315480, 

China 

(4) For the investigation so instituted, 

the Chief Administrative Law Judge, 

U.S. International Trade Commission, 

shall designate the presiding 

Administrative Law Judge. 

Responses to the complaint and the 

notice of investigation must be 

submitted by the named respondent in 

accordance with section 210.13 of the 

Commission’s Rules of Practice and 

Procedure, 19 CFR 210.13. Pursuant to 

19 CFR 201.16(e) and 210.13(a), as 

amended in 85 FR 15798 (March 19, 

2020), such responses will be 

considered by the Commission if 

received not later than 20 days after the 

date of service by the complainants of 

the complaint and the notice of 

investigation. Extensions of time for 

submitting responses to the complaint 

and the notice of investigation will not 

be granted unless good cause therefor is 

shown. 

Failure of the respondent to file a 

timely response to each allegation in the 

complaint and in this notice may be 

deemed to constitute a waiver of the 

right to appear and contest the 

allegations of the complaint and this 

notice, and to authorize the 

administrative law judge and the 

Commission, without further notice to 

the respondent, to find the facts to be as 

alleged in the complaint and this notice 

and to enter an initial determination 

and a final determination containing 

such findings, and may result in the 

issuance of an exclusion order or a cease 

and desist order or both directed against 

the respondent. 

By order of the Commission. 

Issued: December 12, 2024. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2024–29906 Filed 12–17–24; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–1444] 

Importer of Controlled Substances 

Application: Leading Pharma LLC 

AGENCY: Drug Enforcement 

Administration, Justice. 

ACTION: Notice of application. 

SUMMARY: Leading Pharma LLC to be 

registered as an importer of basic 

class(es) of controlled substance(s). 

Refer to Supplementary Information 

listed below for further drug 

information. 

DATES: Registered bulk manufacturers of 

the affected basic class(es), and 

applicants, therefore, may submit 

electronic comments on or objections to 

the issuance of the proposed registration 

on or before January 17, 2025. Such 

persons may also file a written request 

for a hearing on the application on or 

before January 17, 2025. 

ADDRESSES: The Drug Enforcement 

Administration requires that all 

comments be submitted electronically 

through the Federal eRulemaking Portal, 

which provides the ability to type short 

comments directly into the comment 

field on the web page or attach a file for 

lengthier comments. Please go to 

https://www.regulations.gov and follow 

the online instructions at that site for 

submitting comments. Upon submission 

of your comment, you will receive a 

Comment Tracking Number. Please be 

aware that submitted comments are not 

instantaneously available for public 

view on https://www.regulations.gov. If 

you have received a Comment Tracking 

Number, your comment has been 

successfully submitted and there is no 

need to resubmit the same comment. All 

requests for a hearing must be sent to: 

(1) Drug Enforcement Administration, 

Attn: Hearing Clerk/OALJ, 8701 

Morrissette Drive, Springfield, Virginia 

22152; and (2) Drug Enforcement 

Administration, Attn: DEA Federal 

Register Representative/DPW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for a hearing should 

also be sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. 

SUPPLEMENTARY INFORMATION: In 

accordance with 21 CFR 1301.34(a), this 

is notice that on September 27, 2024, 

Leading Pharma LLC, 3 Oak Road, 

Fairfield, New Jersey 07004, applied to 

be registered as an importer of the 

following basic class(es) of controlled 

substance(s): 

Controlled 

substance Drug code Schedule 

Diphenoxylate ... 9170 II 

The company plans to import the 

listed controlled substance as an 

importer active pharmaceutical 

ingredient for research and development 

toward manufacturing a finished dosage 

product for Food and Drug 

Administration approval. No other 

activity for this drug code is authorized 

for this registration. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under 21 U.S.C. 952(a)(2). 

Authorization will not extend to the 

import of Food and Drug 

Administration-approved or nonapproved finished dosage forms for 

commercial sale. 

Matthew Strait, 

Deputy Assistant Administrator. 

[FR Doc. 2024–29997 Filed 12–17–24; 8:45 am] 

BILLING CODE 

DEPARTMENT OF JUSTICE 

[OMB Number 1117–0053] 

Agency Information Collection 

Activities; Proposed eCollection 

eComments Requested; Leadership 

Engagement Survey (LES) 

AGENCY: Drug Enforcement 

Administration, Department of Justice. 

ACTION: 30-Day notice. 

SUMMARY: The Drug Enforcement 

Administration, Department of Justice 

(DOJ), will be submitting the following 

information collection request to the 

Office of Management and Budget 

(OMB) for review and approval in 

accordance with the Paperwork 

Reduction Act of 1995. 

DATES: Comments are encouraged and 

will be accepted for 30 days until 

January 10, 2025. 

FOR FURTHER INFORMATION CONTACT: If 

you have comments especially on the 

estimated public burden or associated 

response time, suggestions, or need a 

copy of the proposed information 

collection instrument with instructions 

or additional information, please 


khammond on DSK9W7S144PROD with NOTICES